Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. announced that it will release its third-quarter 2025 financial results before the market opens on Tuesday, October 28, 2025. The company will host a conference call and webcast at 9 a.m. ET the same day to discuss the results, and the earnings press release with related financial information will be posted on the Labcorp Investor Relations website.
The announcement is furnished through a press release dated September 25, 2025, which is included as Exhibit 99.1 to this report and incorporated by reference.
Labcorp Holdings Inc. announced that members of its executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The session is scheduled for Tuesday, September 9, at 7:45 a.m. ET and will focus on the company’s role as a global provider of innovative and comprehensive laboratory services.
A live audio webcast of the discussion will be available through Labcorp’s investor relations website at ir.Labcorp.com, and the recording will be archived for replay. The company furnished a related press release as Exhibit 99.1 to this report.
Sandra D. van der Vaart, identified as EVP, Chief Legal Officer of Labcorp Holdings Inc. (LH), reported offsetting option exercise and share sale transactions dated 08/13/2025. She exercised 3,903 non-qualified stock options with an exercise price of $131.43 per share, resulting in the acquisition of 3,903 common shares. On the same date she sold 3,903 common shares at a reported price of $271.4249 per share. The filing shows 6,176.6691 shares beneficially owned after the acquisition line and 2,273.6691 shares after the sale line. The options were granted under the company omnibus plan, vesting began 02/12/2020 and are exercisable through 02/11/2029. An additional 30.1294 shares were included from the employee stock purchase plan.
Labcorp Holdings Inc. (LH) filed a Form 144 reporting a proposed sale of 3,903 shares of common stock with an aggregate market value of $1,059,371.39. The filing lists 83,100,000 shares outstanding and names Fidelity Brokerage Services as the broker; the sale is slated for 08/13/2025 on the NYSE.
The filing shows the securities were acquired via an option granted on 02/12/2019, with acquisition and payment dated 08/13/2025, and payment made in cash. It also reports no securities sold in the past three months for the selling person and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Adam H. Schechter, President & CEO and Director of Labcorp Holdings Inc. (LH), reported a sale of company common stock on 08/11/2025. The Form 4 discloses that 5,643 shares were disposed of at a reported price of $266.78 per share pursuant to a plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The filing was executed by an attorney-in-fact on 08/13/2025.
After the reported transaction Schechter beneficially owns 93,319 shares directly. No derivative transactions are reported on this Form 4. The disclosure identifies the transaction code as an S-sale under the stated 10b5-1 plan.
Labcorp Holdings Inc. insider notice reports a proposed sale of 5,643 common shares for an aggregate market value of $1,505,439.54, to be executed through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/11/2025. The shares were acquired on 03/30/2023 by restricted stock vesting as compensation. The filing also shows the seller previously sold 6,105 shares on 05/12/2025 for gross proceeds of $1,518,496.65. The issuer's total outstanding common shares are reported as 83,100,000. By signing, the seller represents no undisclosed material adverse information and notes the compliance statements relevant to Rule 144 and Rule 10b5-1.
Labcorp Holdings (LH) – insider sale by finance executive
Form 4 filed 07/31/2025 details that SVP & Chief Accounting Officer Peter J. Wilkinson sold a total of 202 common shares on 07/29/2025 in two open-market transactions: 102 shares at $261.0102 and 100 shares at $261.035. Estimated gross proceeds equal roughly $52.7 k. Following the sales, Wilkinson’s direct ownership fell to 1,852.2194 shares. No derivative securities were reported.
The activity modestly reduces the executive’s stake and is immaterial relative to Labcorp’s share count, though investors may note it when tracking insider sentiment.